IMN’s Virtual Investors’ Conference on Biotech ABS, taking place May 6, will provide a platform to understand the intersection of securitization across the biotech and healthcare sector, helping educate investors, borrowers and industry participants on the hottest new asset class in equity capital markets. This one-day virtual conference will focus on both European and U.S. opportunities and challenges, as regulatory challenges will be forefront on both sides of the globe.

Biotech issuance in 2020 surpassed $60 billion globally, spurring this asset class to become the second most popular equity capital markets sector, with momentum driven by huge secondary moves and companies benefitting from a greater focus on healthcare investing that Covid-19 has generated.

Join this must-attend gathering to engage with hedge funds, institutional investors, and more, to discover exciting new investment opportunities as this sector expands to comply with policy, market demand and changing consumer needs.

Conference website